soul trial oral semaglutide cardiovascular outcomes 2024 nejm Reduces CV Events in T2DM β (NEJM, Mar 2025) Relevant for: cardiology, diabetology, nephrology, internal medicine π§ͺ T2DM + ASCVD/CKD π Oral semaglutide 14 mg vs placebo π Semaglutide and Cardiovascular Outcomes in
Description
Support your body's natural GLP-1 signaling with a gut-first formula designed to promote appetite balance, healthy blood sugar and glucose metabolism, and steady energy.
ENERGY & PERFORMANCE: Supports energy levels, stamina, physical performance, and muscle strength
Heres what to know to avoid surprises and save where you can.
Lets talk #science, not shortcuts
These medications exert (in)direct hepatic actions by reducing steatosis, attenuating inflammation, and potentially reversing fibrosis, while simultaneously addressing systemic metabolic abnormalities including excessive obesity, insulin resistance, and cardiovascular risk
Similarly, over a 12-month period, 417% of insulin-treated patients reported needing assistance and 3764% experienced any hypoglycemic symptoms
